# Merck & Co. Type: Company (MRK) Source: GetYourBrief — https://getyourbrief.com/entity/merck-co Canonical HTML page: https://getyourbrief.com/entity/merck-co ## Timeline - **2030-12-31**: Target Deadline — Goal for participating nations to reach the 90-70-90 elimination milestones. - **2030-12**: Elimination Target — Deadline for reaching the 90-70-90 vaccination, screening, and treatment goals. - **2028**: Keytruda Patent Cliff — Merck faces the loss of exclusivity for its top-selling cancer immunotherapy. - **2026-07-16**: FDA approves Merck's Lipfendra — The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients. - **2026**: Expected Closing — Anticipated completion of the acquisition following regulatory reviews. - **2026-05**: Marty Makary resigns as FDA Commissioner — Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure. - **2026-03-25**: Acquisition Announcement — Merck announces definitive agreement to buy Terns for $6.7 billion. - **2026-03-20**: Federal Injunction — A federal judge issues a temporary block on the administration's vaccine agenda, citing public health risks. - **2026-03-15**: Expected Response — The Trump administration is expected to file its initial legal defense regarding executive agency authority. - **2026-03-10**: Fund Launch — Jacinda Ardern officially unveils the dedicated fund for Pacific cervical cancer elimination. - **2026-03-04**: FY 2025 Earnings — Official reporting of full-year financial results and 2026 clinical guidance. - **2026-03**: $5.1M Grant Awarded — Major funding secured to scale screening and vaccination across the region. - **2026-02-25**: Public Announcement — Arizona and other state attorneys general publicly detail the health risks associated with the vaccine rollback. - **2026-02-24**: Lawsuit Filed — A coalition of states files a formal complaint against the Trump administration in federal court. - **2026-02-15**: Proposed Schedule Changes — The administration proposes sweeping changes to the national pediatric immunization schedule. ## Recent coverage (14 stories, network-wide) ### Oncologists Worldwide Cut Opdivo Doses by up to 92%, Defying FDA's 1-Year Rule 2026-08-20 09:12:50 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2 A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts. Full story: https://gethealthbrief.com/story/fda-cancer-drug-dosing-challenge-health-systems ### Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate 2026-08-20 09:12:41 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data. Full story: https://getbiobrief.com/story/biotech-cancer-drug-dosing-challenge-keytruda-opdivo ### Merck's Lipfendra: 59% LDL Cut with First Oral PCSK9 Pill Approved 2026-07-16 23:20:10 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 7 The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol. Full story: https://gethealthbrief.com/story/merck-lipfendra-oral-pcsk9-pill-59-percent-ldl-cut-health-systems ### Merck to Acquire Terns Pharmaceuticals in $6.7B Hematology Push 2026-03-25 19:19:17 · Sector: finance · Sentiment: Positive · Impact: 8/10 · Sources: 2 Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda. Full story: https://getfinancebrief.com/story/merck-terns-pharmaceuticals-acquisition-leukemia ### Merck Bolsters Oncology Pipeline with $6.7B Acquisition of Terns Pharmaceuticals 2026-03-25 19:17:39 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2 Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda. Full story: https://gethealthbrief.com/story/merck-acquires-terns-pharmaceuticals-leukemia-deal ### Federal Judge Temporarily Blocks RFK Jr.’s Vaccine Policy Overhaul 2026-03-21 00:48:17 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 6 A federal judge has issued a temporary injunction against Robert F. Kennedy Jr.’s proposed changes to national vaccine policy, citing potential risks to public health. The ruling provides a reprieve for pharmaceutical manufacturers and public health agencies while the legal merits of the administration's agenda are debated. Full story: https://getbiobrief.com/story/federal-judge-blocks-rfk-jr-vaccine-agenda ### South Carolina Spends $1.6M on Ongoing Measles Outbreak as Costs Mount 2026-03-13 21:34:29 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 South Carolina health officials have already allocated $1.6 million to contain a significant measles outbreak that shows no signs of immediate resolution. The expenditure highlights the massive economic burden of vaccine-preventable diseases on state public health infrastructures. Full story: https://getbiobrief.com/story/south-carolina-measles-outbreak-costs-2026 ### Ardern-Led Fund Targets Cervical Cancer Elimination Across Pacific Islands 2026-03-10 03:35:13 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Former New Zealand Prime Minister Jacinda Ardern has launched a dedicated health fund to combat the disproportionately high rates of cervical cancer in Pacific Island nations. The initiative focuses on scaling HPV DNA testing and vaccination programs to meet WHO elimination targets by 2030. Full story: https://getbiobrief.com/story/jacinda-ardern-fund-cervical-cancer-pacific ### $5.1M Grant Targets Cervical Cancer Elimination Across the Pacific 2026-03-08 00:13:22 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 A new $5.1 million grant has been awarded to accelerate cervical cancer elimination efforts across the Pacific region, focusing on HPV vaccination and advanced screening. The initiative aligns with the WHO's global strategy to eradicate the disease through the 90-70-90 targets by 2030. Full story: https://getbiobrief.com/story/pacific-cervical-cancer-elimination-grant-2026 ### Keros Therapeutics Strengthens TGF-β Pipeline as 2025 Financials Signal Growth 2026-03-04 23:38:04 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026. Full story: https://getbiobrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis ### 15 States Sue Trump Administration Over Childhood Vaccine Schedule Changes 2026-02-25 23:30:56 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 California and 14 other states have filed a federal lawsuit against the Trump administration, challenging recent modifications to the recommended childhood immunization schedule. The coalition argues that these changes lack scientific justification and threaten to undermine decades of public health progress. Full story: https://getbiobrief.com/story/15-states-sue-trump-vaccine-schedule ### States Sue Trump Administration Over Childhood Vaccine Recommendation Rollback 2026-02-25 13:01:20 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 A coalition of over a dozen states, led by Arizona, has filed a federal lawsuit against the Trump administration to block the rollback of childhood vaccine recommendations. The plaintiffs argue that the changes to CDC guidelines bypass scientific protocols and present an immediate threat to national public health safety. Full story: https://getbiobrief.com/story/states-sue-trump-vaccine-rollback ### 15 States Sue Trump Administration Over Rollback of Childhood Vaccine Schedule 2026-02-25 13:00:11 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2 A coalition of 15 Democratic-led states has filed a lawsuit against the Trump administration to block changes that reduce the recommended childhood vaccine schedule. The plaintiffs argue that the policy shift ignores scientific consensus and poses a significant risk of infectious disease outbreaks across the country. Full story: https://gethealthbrief.com/story/states-sue-trump-administration-vaccine-schedule-rollback ### Chikungunya Transmission Risk Expands Across Europe Amid Climate Shift 2026-02-19 12:54:45 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 A landmark study reveals that the excruciating tropical disease Chikungunya is now capable of local transmission across most of Europe. Driven by the northward migration of the Aedes albopictus mosquito, this shift creates an urgent demand for vaccines and diagnostic infrastructure in previously unaffected regions. Full story: https://getbiobrief.com/story/chikungunya-transmission-risk-europe-pharma-impact --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.